

1 **Hyperreflective foci, OCT progression indicators in age-related macular**
2 **degeneration, include transdifferentiated retinal pigment epithelium**

3

4 **Dongfeng Cao PhD^{1‡}, Belinda Leong MD^{2,4‡}, Jeffrey D. Messinger DC¹, Deepayan**
5 **Kar MS¹, Thomas Ach MD⁵, Lawrence A. Yannuzzi MD^{2,3}, K. Bailey Freund MD^{2,3,6},**
6 **Christine A. Curcio PhD^{1*}**

7 ¹Department of Ophthalmology and Visual Sciences, University of Alabama at
8 Birmingham School of Medicine; Birmingham, AL, USA.

9 ²Vitreous Retina Macula Consultants of New York; New York, NY, USA.

10 ³LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital;
11 New York, NY, USA.

12 ⁴Retina Associates; Sydney, NSW, Australia.

13 ⁵Department of Ophthalmology, University Hospital Bonn; Bonn, Germany.

14 ⁶Department of Ophthalmology, New York University, Grossman School of Medicine;
15 New York, NY, USA.

16

17 ***Corresponding author. Email: christinecurcio@uabmc.edu**

18 **‡**These authors contributed equally to this work.

19 **Short title:** RPE transdifferentiation in AMD

20 **Words:** 4676 (main), **Figures:** 9; **Supplementary figures:** 7; **Supplementary tables:** 7

21

22 Previous meeting presentations: annual meeting of the Association for Research in
23 Vision and Ophthalmology, 2019 (clinical imaging) and 2020 (laboratory study)

24

25 **ABSTRACT**

26 Purpose: By optical coherence tomography (OCT) imaging, hyperreflective foci (HRF)
27 indicate progression risk for advanced age-related macular degeneration (AMD) and are
28 in part attributable to ectopic retinal pigment epithelium (RPE). We hypothesized that
29 ectopic RPE are molecularly distinct from in-layer cells and that their cross-retinal course
30 follows Müller glia.

31 Method: In clinical OCT (61 eyes, 44 AMD patients, 79.4 ± 7.7 years; 29 female; follow-
32 up = 4.7 ± 0.9 years) one HRF type, RPE plume, was reviewed. Twenty eyes of 20
33 donors characterized by *ex vivo* OCT were analyzed by histology (normal, 4;
34 early/intermediate AMD, 7; geographic atrophy (GA), 6; 3 neovascular AMD (nvAMD).
35 Cryosections were stained with antibodies to retinoid (RPE65, CRALPB) and immune
36 (CD68, CD163) markers. In published RPE cellular phenotypes, red immunoreactivity
37 was assessed semi-quantitatively by one observer (none, some cells, all cells).

38 Results: Trajectories of RPE plume and cellular debris paralleled Müller glia, whether
39 ordered or subsident, near atrophy borders. RPE corresponding to HRF lost
40 immunoreactivity for retinoid markers and gained immunoreactivity for immune markers.
41 Aberrant immunoreactivity appeared in individual in-layer RPE cells and extended to all
42 abnormal phenotypes. Müller glia remained CRALBP-positive. Plume cells approached
43 and contacted retinal capillaries.

44 Conclusion: Gain- and loss-of-function starts with individual in-layer RPE cells and
45 extends to all abnormal phenotypes. Down-regulated RPE retinoid handling may impair
46 rod vision while Müller glia sustain cone vision. Evidence for RPE transdifferentiation,
47 possibly due to ischemia, supports a proposed process of epithelial-mesenchyme
48 transition. Data can propel new biomarkers and therapeutic strategies for AMD.

49

50 **Key words:** age-related macular degeneration, hyperreflective foci, retinal pigment
51 epithelium, optical coherence tomography, immunohistochemistry, retinoids, immune
52 markers, epithelial-mesenchyme transition

53

54 **Abbreviations:** AMD, Age-related macular degeneration; OCT, optical coherence
55 tomography; HRF, hyperreflective foci; BLamD, basal laminar deposit; BrM, Bruch's
56 membrane; Ch, choroid; ChC, choriocapillaris; cRORA, complete RPE and outer retinal
57 atrophy; d, drusen; ELM, external limiting membrane; EZ, ellipsoid zone; fv scar,
58 fibrovascular scar; GCL, Ganglion cell layer; HFL, Henle fiber layer; ILM, internal limiting
59 membrane; IPL, inner plexiform layer; INL, inner nuclear layer; IS, inner segments of
60 photoreceptors; iRORA, complete RPE and outer retinal atrophy; IZ, interdigitation zone;
61 nvAMD, neovascular AMD; ONL, outer nuclear layer; OPL, outer plexiform layer; OS,
62 outer segments of photoreceptors; R, retina; RPE, retinal pigment epithelium; Sc, sclera;
63 SRS, subretinal space; x, detachment.

64

65 **Précis:** Hyperreflective foci (HRF) are OCT progression risk indicators in age-related
66 macular degeneration. Abnormal RPE cells including some that correspond to HRF lose
67 immunoreactivity for retinoid markers and gain immunoreactivity for immune markers,
68 indicating molecular transdifferentiation.

69

70

71 **INTRODUCTION**

72 Age-related macular degeneration (AMD) causes vision loss in older persons worldwide.

73 ¹ Neovascular complications are managed medically, ² whereas the underlying and
74 prevalent atrophic (“dry”) disease is not yet treatable. AMD affects vertically integrated
75 cellular layers formed by light-sensing photoreceptors and support cells (retinal pigment
76 epithelium (RPE), choriocapillaris, Müller glia). Characteristic extracellular deposits
77 (drusen, subretinal drusenoid deposits) form between photoreceptors and their choroidal
78 and retinal blood supplies. ³

79 AMD is increasingly understood via clinical optical coherence tomography (OCT).
80 This technology provides depth-resolved and registered images of retinal and choroidal
81 tissue layers ⁴ that resemble histology and can be followed over time. ⁵ Not only are RPE
82 cells central to, and impacted by, both atrophic and neovascular AMD, they can be
83 uniquely monitored in vivo by OCT. RPE health is also an OCT readout of the less
84 visible Bruch’s membrane and choriocapillaris. Each RPE cell has >1400 organelles ⁶
85 capable of generating OCT reflectivity. Further, as neovascular AMD is managed
86 clinically, many OCT images of at-risk eyes are captured. A progression sequence for
87 drusen-initiated atrophy supported by OCT and histology is age-related deterioration of
88 choriocapillaris and Bruch’s membrane preventing egress of wastes to the circulation,
89 growth of drusen with death or migration of overlying RPE, and reactive gliosis. ⁵

90 Longitudinal studies and post-hoc analysis of clinical trial imaging datasets
91 revealed OCT biomarkers for progression from intermediate AMD to geographic atrophy.
92 Tissue damage in atrophy is severe and possibly irreversible. ⁷ Currently the only
93 imaging outcome accepted by the U.S. Food and Drug Administration for AMD trials is
94 slowing the expansion of atrophy. Identifying outcome measures earlier in disease

95 progression is the goal of an international consensus group.^{5, 8-10} Of OCT biomarkers,
96 hyperreflective foci (HRF) within the neurosensory retina confer the largest progression
97 risk.¹¹⁻¹⁴ Our histologic survey of RPE phenotypes in AMD,¹⁵⁻¹⁷ confirmed in clinically
98 characterized eyes,^{15, 18} identified two RPE phenotypes corresponding to HRF. These
99 are “sloughed” cells in the subretinal space and “intraretinal” cells within the
100 neurosensory retina. In a hypothetical progression sequence ([Fig. 1](#)), morphologically
101 distinct cells deploy along separate pathways of cell fate. These include death,
102 migration, and transdifferentiation to other cell types, without intervening dedifferentiation
103 and proliferation.¹⁹ Due to migration and death-in-place of RPE, the layer disintegrates,
104 scattering fully pigmented and nucleated cells (“dissociated”) across atrophic areas.
105 Some cells appear to dive below the intact layer and migrate outside the atrophic area
106 (“subducted”).¹⁶ In neovascular AMD, lipid filled non-RPE cells also correlated to HRF^{18,}
107²⁰ and may represent microglia, macrophages, or both.

108 We postulated that one HRF form called “RPE plume” represents cells crossing the
109 retina within the Henle fiber layer (HFL), which varies in thickness and angle with retinal
110 position (Supplementary Fig. 1).¹⁷ We herein provide a clinical OCT description for this
111 feature in patients with AMD and show RPE-derived debris in relation to the cross-retinal
112 course of Müller glia. To probe the identity of HRF and test whether they include
113 transdifferentiated RPE, we used immunohistochemistry of human donor eyes to show
114 loss of retinoid processing and gain of immunologic function in all abnormal RPE
115 phenotypes. Widespread RPE transdifferentiation, consistent with a proposed process of
116 epithelial-mesenchyme transition,²¹ supports a strategy of visualizing and targeting
117 pathology earlier in AMD progression than atrophy.

118

119 **MATERIALS AND METHODS**

120 **Compliance**

121 Study of a clinical cohort and use of human tissue samples was approved by institutional
122 review at Vitreous Macula Retina and University of Alabama at Birmingham (IRB-
123 150910011), respectively, and complied with the Health Insurance Portability and
124 Accountability Act of 1996 and the Declaration of Helsinki.

125

126 **Patient selection, clinical image capture, and image analysis**

127 Consensus nomenclature was used for reflective bands of OCT.²² RPE+BL band refers
128 to the RPE and its basal lamina atop drusen or other material in the sub-RPE-BL space.
129 This space is between RPE-BL and inner collagenous layer of Bruch's membrane.²³

130 To analyze RPE plume natural history, patients with non-neovascular AMD on
131 OCT imaging seen by specialists (authors KBF, LAY) at a tertiary private retinal practice
132 were retrospectively reviewed (author BL). Inclusion criteria included age >50 years, >12
133 months of follow-up with tracked OCT B-scans at an inter-scan spacing of ≤ 250 μm , and
134 maximum follow-up interval of 6 months, and at least one eye containing HRF. HRF
135 were defined as features with reflectivity like that of the RPE, separated from the RPE
136 layer (i.e., discrete HRF), and thought to originate from the RPE layer. Reduced
137 RPE+BL thickness in a scan subsequent to HRF appearance was considered evidence
138 for RPE origin. Patients with diabetic retinopathy, retinal vascular disease, previous
139 vitreoretinal surgery, laser treatment or ocular inflammation were excluded. Eyes were
140 evaluated at baseline by presence of AMD lesions including soft and cuticular drusen,
141 subretinal drusenoid deposits, and acquired vitelliform lesions²⁴). If color fundus
142 photographs were available, pigmentary changes were also considered. Presence of

143 drusenoid pigment epithelial detachment²⁵ and complete RPE and outer retinal atrophy
144 (cRORA)⁹ was noted.

145 All patients underwent spectral domain OCT and near-infrared reflectance imaging
146 (Spectralis HRA + OCT, Heidelberg Engineering, Heidelberg, Germany) with eye
147 tracking enabled. The OCT protocol comprised 20° horizontal raster line scans centered
148 on the fovea (19 to 49 B-scans per eye; scan spacing at 115 to 250 µm, automatic real-
149 time averaging between 4 and 23).

150 Consecutive tracked OCT and near-infrared reflectance images were analyzed
151 over time and with reference to the foveal center, from the date of HRF appearance.
152 Plume status over time was recorded as no change, change to a different morphology,
153 formation of a discrete HRF as defined above, and dissolution. Plume direction towards
154 the OPL was noted as congruent or incongruent with normal HFL architecture
155 (Supplementary Fig. 1), i.e., parallel or non-parallel with fibers. To evaluate plumes as
156 progression indicators, expansion of cRORA and drusen growth and collapse were also
157 noted.

158

159 **Overview of laboratory studies**

160 To elucidate the molecular repertoire of RPE phenotypes corresponding to HRF,
161 we obtained human donor eyes with and without AMD and performed
162 immunohistochemistry. We used antibodies for retinoid- and immune-related proteins²⁶
163 (Supplementary Table 1) and positive and negative controls in human tissues
164 (Supplementary Fig. 2). Cryosections were processed with an avidin-biotin-peroxidase
165 immunohistochemistry detection system and a red reaction product. We checked the
166 immunolabeling of all RPE phenotypes²⁷ (Supplementary Table 2) using bright field

167 microscopy for direct observation of cellular pigmentation and status of surrounding
168 tissue.

169

170 **Donor eye acquisition, ex vivo imaging, AMD diagnosis**

171 Whole eyes were obtained from deceased human donors (≥ 80 years of age,
172 white, non-diabetic, and ≤ 6 hours death-to-preservation) to the Advancing Sight Network
173 (Birmingham AL USA) during 2016-17. Eye health history was not available. After
174 anterior segment removal, eyes were preserved in 4% buffered paraformaldehyde,
175 screened for AMD using *ex vivo* multimodal imaging including OCT¹⁷ (details in
176 Results). Tissues were stored in 1% buffered paraformaldehyde at 4°C until used.

177 Rectangles of full-thickness eye wall (5x8 mm) including fovea and optic nerve
178 were dissected. To prevent ice crystals, tissue was cryoprotected in ascending
179 concentrations of sucrose in phosphate buffered saline (PBS) then ascending
180 concentrations of tissue embedding medium and sucrose buffer (HistoPrep, Thermo
181 Fisher Scientific, #SH75-1250D, Rockford IL USA); 4 parts sucrose buffer and 1 part
182 medium then 2:1 sucrose: medium. Tissue was placed into a cryomold (Electron
183 Microscopy Sciences, #70176-10, Fort Washington PA USA) with embedding medium,
184 oriented, frozen in liquid nitrogen, and stored at -80°C. Tissues were sectioned at 12 μm
185 thickness on a cryostat (Leica CM3050 Vashaw Scientific, Norcross GA USA), air dried
186 at 37°C overnight, and stored at -80°C until used.

187 For AMD diagnosis and imaging-histology correlation, cryosections through the
188 fovea and perifovea (recognized by HFL) were stained with periodic acid Schiff
189 hematoxylin to highlight Bruch's membrane and sub-RPE deposits. One stained section
190 per slide was scanned with a 20X objective and a robotic microscope stage (Olympus

Cao, Leong et al, RPE transdifferentiation in AMD

191 VSI 120, CellSens; Olympus, Center Valley PA), scaled to tissue units, and centered on
192 the fovea or vertical meridian (where Henle fibers diverge) using a custom plugin for FIJI
193 (<https://imagej.nih.gov/ij/download.html>). *Ex vivo* OCT B-scans and scanned whole
194 sections were matched for major landmarks (e.g., overall tissue contour, foveal center,
195 large vessels, individual pathologies). For detailed examination, some sections were
196 scanned with a 60X oil immersion objective (numerical aperture = 1.4). For figures,
197 images were adjusted to maximize the intensity histogram for contrast and white balance
198 and made into composites (Photoshop CS6, Adobe Systems, USA).

199

200 **Immunohistochemistry and evaluation**

201 Detailed methods for immunohistochemistry are available in the Supplementary
202 Materials.

203 Glass slides were scanned using the system described above and 20x and 40x
204 objectives. RPE phenotype was categorized using the Project MACULA grading system.
205 ^{15, 16} (Supplementary Table 2). In each stained section (1 per antibody per eye),
206 immunoreactivities for each RPE phenotype were scored semi-quantitatively by a single
207 observer (author DC after training by author CAC) as 0-not stained, 1-some stained and
208 2- all stained. These scores were converted to percentages using by total scores of eyes
209 for each phenotype divided by maximum score (2 x number of eyes with the phenotype)
210 times 100. Each phenotype was seen in at least 3 eyes.

211

212

213 **RESULTS**

214 **Clinical imaging**

215 Four morphologies of RPE plume were defined (Fig 2). Curvilinear plumes (Fig. 2A)
216 appear as hyperreflective features of constant width, above the RPE layer with or
217 without drusen, and pointing towards the outer plexiform layer. Relative to curvilinear,
218 comma plumes (Fig. 2B) are similarly reflective, with a wider base at the RPE layer and
219 tapering anteriorly. Like curvilinear, thread plumes (Fig. 2C), previously seen in inherited
220 retinopathies,²⁸ are of uniform width but are thinner. A vitelliform plume (Fig. 2D) is thick
221 at its base, typically an acquired vitelliform lesion (autofluorescent and yellow subretinal
222 extracellular material),²⁴ with an anterior taper that widens over time.

223 To observe plume lifecycles and intraretinal trajectories, 44 patients with non-
224 neovascular AMD (61 eyes, 29 females, 79.4 years (standard deviation 7.7 years)) with
225 at least one HRF were enrolled (Supplementary Table 3). In 29 eyes of 21 patients (15
226 female), 129 plumes were localized and followed for characteristics including presence
227 of cRORA and iRORA).^{5,9} Mean follow-up duration was 4.67 years (standard deviation
228 0.09 years). As shown in Supplementary Fig. 3A-B, plumes obliquely crossing
229 horizontally oriented OCT B-scans appeared as small reflective dots that were
230 connected by inspecting consecutive scans. Over time individual plumes evolved
231 considerably (Fig. 3), converting from one morphology to another (Fig. 3B,D,E) or to
232 discrete HRF as defined above (Fig. 3C). They also disappeared with (Fig. 3A,B,D) or
233 persisted after (Fig. 3A, B, C, D) druse collapse to atrophy. One plume preceded druse
234 appearance (Fig. 3E).

235 Curvilinear and thread plumes were the most common morphologies at baseline
236 and the longest lasting over follow up (Supplementary Fig. 4A). Plume number and

Cao, Leong et al, RPE transdifferentiation in AMD

237 dynamism (i.e., appearance, disappearance, and conversions) could be striking
238 (Supplementary Fig. 4B). Of 129 plumes at baseline (Supplementary Table 4), 73
239 (56.6%) converted to another plume morphology or discrete HRF during follow-up, with
240 38 disappearing and 35 remaining; 56 (43.4%) plumes retained the original morphology.

241 Most plumes (101/129, 78.3%) were geometrically congruent with the local
242 trajectory of the normal HFL (Supplementary Table 5), especially temporal to the fovea.
243 More non-congruent plumes appeared superior nasal to the fovea than in other
244 quadrants. Of 129 plumes, 73 (56.6%) were associated with cRORA. Near cRORA,
245 plumes were seen traveling in directions unrelated or opposite to the normal HFL
246 (Supplementary Fig. 5). Accordingly, at the final visit (Supplementary Table 6), 48 of 129
247 (37.2%) plumes associated with cRORA were congruent with the local normal HFL and
248 25 of 129 (19.4%) were incongruent, with 16/129 (12.4%) of incongruent plumes located
249 at the cRORA border. In contrast, all 6/129 (4.7%) plumes associated with iRORA were
250 congruent with the HFL. Finally, 50/129 (38.8%) of plumes were not associated with
251 either cRORA or iRORA.

252

253 **Laboratory study**

254 To molecularly characterize normal and abnormal RPE cells, especially those
255 corresponding to HRF, we used *ex vivo* OCT imaging to find human donor eyes with
256 AMD ([Fig. 4](#)). HRF found in macular OCT B-scans were matched with pigmented cells in
257 the subretinal space and retina of stained sections ([Fig. 4](#)). Atrophic AMD eyes with RPE
258 plume in OCT exhibited pigmented cells in the outer nuclear layer (ONL) and HFL on
259 histology ([Fig. 4, C1 to C2 and F1 to F2](#)). Results are based on 20 eyes of 20 donors
260 (mean age 89.2 ± 5.0 years; 16 total AMD (7 early-intermediate, 6 atrophic, 3

261 neovascular, 4 control), with mean time from death to preservation of 3.9 ± 0.7 hours
262 (Supplementary Table 7).

263 *Gain of immune function*

264 We begin by demonstrating that cells of RPE origin label with antibodies against
265 two well-known immune cell markers, Cluster of Differentiation (CD)68 and CD163.²⁹
266 CD68 is a transmembrane glycoprotein that is abundantly expressed by macrophages
267 and widely used as a myeloid-specific marker.³⁰ CD68 is one member (LAMP-4) of a 5-
268 protein family that together accounts for 50% of the protein in lysosome membranes.³⁰
269 In tissue sections (Fig. 5), positive controls for CD68 immunoreactivity are choroidal
270 macrophages (Fig. 5D) and negative controls are healthy RPE (Fig. 5A). Fully
271 pigmented cells in the neurosensory retina are strongly CD68+ (Fig. 5F). Importantly,
272 individual sloughed cells in the subretinal space (Fig. 5C and 5F) are also positive, as
273 are individual cells still within the layer (Fig. 5E). Dissociated RPE scattered in the
274 atrophic area are universally labeled (Fig. 5H and 5N), as are cells under the continuous
275 layer (Fig. 5I), and within tubes of scrolled photoreceptors (Fig. 5J and 5K; outer retinal
276 tubulation³¹). Some bilaminar (Fig. 5D) and melanotic (Fig. 5M) cells are CD68+.

277 CD163 is a high-affinity haptoglobin-hemoglobin scavenger found in bone marrow-
278 derived macrophages³² and in retinal cells resembling microglia.³³⁻³⁵ The latter are
279 phagocytes of embryologic yolk sac origin that reside in inner retina when quiescent and
280 migrate into outer retina when photoreceptors are damaged.³³ Figure 6 shows that anti-
281 CD163 labels inner retina cells but not the normal RPE layer, as expected. It does label
282 abnormal RPE phenotypes in a pattern like that of CD68, with overall lighter reaction
283 product. These include fully pigmented CD163+ cells in the ONL (Fig. 6F and 6N), HFL
284 (Fig. 6L), above (Fig. 6E and 6I) and below (Fig. 6I) the continuous RPE layer in the

285 subretinal and sub-RPE-basal laminar spaces, respectively, and dissociated cells in
286 atrophic areas ([Fig. 6 H, 6J and 6K](#)).

287 *Loss of retinoid function*

288 Next, we show that abnormal RPE cells cease to exhibit detectable quantities of
289 retinoid processing proteins essential for vision. Rod-mediated (dim light) vision is
290 affected early in AMD, because rods depend on the choriocapillaris-Bruch's membrane-
291 RPE complex.³⁶ Cone-mediated (bright light) vision, which is also sustained by Müller
292 glia and retinal vessels,³⁷ persists into later disease.

293 We begin with RPE65, the isomerohydrolase of the classic visual cycle. RPE65
294 catalyzes the conversion of retinyl esters to 11-cis-retinol, which is subsequently
295 oxidized to 11-cis-retinal, required for visual transduction by rod and cone
296 photoreceptors.³⁸ [Figure 7](#) shows that in AMD eyes, intraretinal RPE in ONL ([Fig. 7F](#))
297 and individual sloughed cells overlying the continuous layer ([Fig. 7C and 7L](#)) lack
298 RPE65-immunoreactivity. Cells in areas of photoreceptor degeneration and depletion
299 are also RPE65-, including dissociated ([Fig. 7N](#)), subducted ([Fig. 7I](#)) and entubulated
300 ([Fig. 7J](#)) cells. Importantly, some individual cells in the continuous layer are RPE65- ([Fig.](#)
301 [7F and 7H](#)). Interestingly some bilaminar cells within fibrotic scars of neovascular AMD
302 remain RPE65+ ([Fig. 7M](#)).

303 Cellular retinal binding protein (CRALBP) is important in the RPE-based visual
304 cycle. It is also expressed by Müller glia in a second visual cycle thought to supply
305 cones.^{37, 39} CRALBP is a 36-kDa water-soluble protein with 2 conformational states
306 facilitating intracellular transport of hydrophobic 11-cis retinoids.⁴⁰ [Figure 8](#) shows that
307 healthy RPE has a strong CRALBP signal ([Fig. 8A](#)). In AMD, ectopic RPE in the ONL,
308 recognizable by pigment load, are CRALBP- ([Fig. 8F and 8L](#)). Individual sloughed cells

309 (Fig. 8H and 8L) and in-layer cells (Fig. 8E) are also negative as are pigmented cells in
310 atrophic areas (dissociated, Fig. 8C, 8K and 8N; subducted, Fig. 8I). Shed granule
311 aggregates^{15, 41} are CRALBP-, under a continuous CRALBP+ layer (Fig. 8B, J).

312 In contrast to RPE, Müller glia remain strongly CRALBP+ in their cross-retinal
313 course, regardless of the degree of photoreceptor loss. Distinctive features (Fig. 8L) are
314 the external limiting membrane (junctional complexes between glia and photoreceptors)
315⁴² and pericellular baskets⁴³ around ONL cell bodies. In the HFL of areas with lesser
316 disease involvement, stained Müller glia are parallel and straight (ordered,⁷ Fig. 8L). At
317 the border of atrophy (descent of the external limiting membrane,⁴⁴ Fig. 8C, 8K and 8N)
318 and outer retinal tubulation (Fig. 8J), CRALBP+ fibers curve down towards Bruch's
319 membrane and then head laterally, parallel to it. In some locations immunolabeled fibers
320 zig-zag in parallel, presenting cross-sections of dots and lines (disordered,⁷ Fig. 8F and
321 8N). CRALBP signal also appears in fibrotic scars resulting from neovascular AMD (Fig.
322 8D, 8G and 8M).

323 *Semi-quantitative assessment of immunohistochemistry*

324 The number of stained cells in each RPE phenotype was assessed a semi-
325 quantitatively (0, not stained; 1, some cells of a phenotype stained; 2, all cells stained).
326 These scores were summed and expressed as a percent of the highest possible score,
327 as if all phenotypes had been stained completely by each antibody. Supplementary
328 Figure 6A shows that all RPE phenotypes were found in immuno-stained sections of
329 these 16 AMD eyes, with similar patterns in neighboring sections. Supplementary Figure
330 6B graphically summarizes the marker studies. Age-normal uniform and non-uniform
331 RPE is positive for retinoid markers and negative for immune markers. Abnormal RPE
332 phenotypes have overall less retinoid immunoreactivity (although some stained cells

333 were found at 5%) and universally more immune marker immunoreactivity (up to 75%).

334 Thus, cells corresponding to HRF in OCT are part of an overall pattern of
335 transdifferentiation resulting in gain-of-function and loss-of-function of RPE.

336 *Histology of plume lifecycle*

337 Our clinical study indicated that RPE plumes have lifecycles that are observable in
338 vivo. We previously showed in type 3 (intraretinal) neovascularization that RPE cells
339 contact the deep capillary plexus.¹⁸ [Figure 9, A to C](#) accordingly shows RPE plume cells
340 crossing the HFL to approach and encircle capillaries of this plexus. Cells are nucleated
341 and contain numerous RPE-characteristic spindle-shaped melanosomes and
342 melanolipofuscin granules. Fine processes extend along a capillary ([Fig. 9D](#)).

343 We previously showed RPE organelles in the HFL of photoreceptor-depleted
344 atrophic areas,⁷ suggesting that Müller glia ingested and cleared debris from
345 degenerating RPE. Here we show region-specific distribution of RPE organelles,
346 consistent with the local trajectory of Müller glia. In the macula, Müller glia are Z-shaped.
347⁴⁵ Fibers are oriented vertically in the ONL, obliquely in the HFL, and vertically in the
348 OPL and inner retinal layers (Supplementary Fig. 1). In plumes near the fovea ([Fig. 9E](#)
349 [and 9F](#); [Fig. 6N](#)), fully pigmented RPE cells obliquely cross the HFL, with individual and
350 grouped organelles in the lead. The path turns vertically at the INL and IPL, following a
351 Z-shaped course. In contrast, in the peripheral retina, where Müller glia are vertical,
352 Supplementary Figure 7 shows melanosomes on a vertical track away from RPE above
353 a druse.

354

355 **DISCUSSION**

356 For RPE plume, one HRF type in AMD, we established a clinical lifecycle, including both
357 cRORA and resolution without cRORA, with evidence of clearance by Müller glia. HRF
358 are one of four OCT indicators in a composite risk score for AMD progression (with soft
359 and calcified drusen, plus subretinal drusenoid deposit).⁴⁶ Of these four, HRF confer the
360 largest risk (odds ratio at 24 months, 5.21 (3.29-8.26)),¹³ yet have received histologic
361 investigation only recently, a gap that is herein addressed. We provide strong evidence
362 that ectopic RPE can manifest as HRF, without excluding the possibility that other cells,
363 such as microglia, macrophages, or both, may also correspond to HRF, as they do in
364 nvAMD.^{18,20} We further show that sloughed and intraretinal cells corresponding to HRF
365 are two of many abnormal RPE phenotypes undergoing molecular transdifferentiation.

366 Our parallel findings of CD68 and CD163 immunoreactivity in all abnormal RPE
367 phenotypes adds important new information to a decades-old debate^{47,48} about whether
368 RPE, a phagocyte itself, shares or assumes properties of other phagocytes. This
369 investigation like our previous studies used high resolution comprehensive microscopy
370 to link cells with characteristic RPE organelles^{15,16} to a time course of activity visible
371 through longitudinal clinical imaging. Our cellular phenotyping system¹⁵ built on prior
372 literature and is used by others.^{49,50} We posited that these phenotypes represented
373 discrete steps towards death, migration, or transdifferentiation of individual cells that
374 could be followed over time in OCT due to high RPE reflectivity. In prior electron
375 microscopic analysis of pigmented cells corresponding to HRF⁵¹ we did not observe
376 phagolysosomes, i.e., cytoplasmic vacuoles formed by phagosomes with ingested
377 material fusing with lysosomes, as expected from phagocyte activity. In a separate study
378 of HRF over a large drusenoid pigment detachment,¹⁷ all detectable HRF could be

379 attributed to fully pigmented and nucleated intraretinal cells. In clinical cases of that prior
380 study,¹⁷ HRF appeared in the retina vertically above and several months after
381 disturbances of the RPE layer. Our current data further show that individual in-layer cells
382 and all abnormal phenotypes exhibit CD68 and CD163 immunoreactivity. We cannot
383 exclude the possibility that phagocytes ingest and retain characteristic RPE organelles,
384 seamlessly intercalate into the layer, and either become abnormal phenotypes or induce
385 them. However, extensive transdifferentiation in response to common perturbations is
386 also a parsimonious explanation.

387 We emphasize that snapshot immuno-detection of CD68, a lysosomal protein of
388 unknown function reliably found in macrophages of myeloid origin,³⁰ does not indicate
389 that labeled cells have assumed macrophage behavior. Our data do not imply that
390 macrophages of hematopoietic origin previously shown in choroid and sub-RPE-BL
391 space^{52, 53} started as RPE. Our data do not bear on the identity of CD68+ cells seen by
392 others, e.g., high-passage cultured RPE⁵⁴ and surgically excised neovascular
393 membranes.^{55, 56} In rapidly preserved eyes with experimental laser-injury, individual
394 detached cells atop an intact RPE layer are CD68+⁵⁷ (compare to [Fig. 5C](#) and [Fig. 6C](#)).
395 Recent authors interpreted CD68+ cells in aqueous after RPE tear⁵⁸ and in proliferative
396 vitreoretinopathy⁵⁹ as RPE. CD68+ cells in the outer junctional zone of atrophy in AMD
397 were demonstrated by laser confocal microscopy and immunofluorescence.⁴⁹ This
398 technique does not directly reveal melanin, and the authors did not comment on cellular
399 identity.⁴⁹

400 Our data illuminate subducted cells on the inner collagenous layer of Bruch's
401 membrane containing RPE organelles and originally called "spent RPE".⁶⁰ Using single
402 continuous high-resolution histologic sections of eyes with cRORA, we saw plausible

403 transitional morphologies between fully pigmented RPE outside atrophic areas and
404 flattened cells with fewer organelles in the sub-RPE-BL space.¹⁶ We hypothesized that
405 dissociated RPE in an atrophic area,⁶¹ loosed from constraining junctional complexes,
406 dove under the intact layer and moved into the outer junctional zone to participate in
407 atrophy expansion ([Fig. 1](#)).¹⁶ Herein we show CD68+ and CD163+ cells and highly
408 pigmented RPE65- and CRALBP- cells in the same sub-RPE-BL tissue compartment of
409 the same eyes. The sub-RPE-BL space can harbor macrophages of myeloid origin,
410 multinucleate giant cells, and fibroblasts.⁶² It is possible that co-localized CCR2 and
411 CD18 immunoreactivity in these locations, attributed to macrophages,⁶³ may represent
412 subducted and dissociated RPE, respectively. Multi-label immunohistochemistry is
413 needed to confirm how many subducted cells are RPE-derived. Macrophages that co-
414 express CD68 and CCR7 can be assigned to a “proinflammatory” M1 subset, whereas
415 CD68+ CD163+ macrophages most likely belong to an “anti-inflammatory” M2 subset.⁶⁴
416 Longitudinal studies with higher resolution OCT^{65, 66} may make it possible to detect
417 subducted cells and determine if they promote or retard atrophy expansion, of value to
418 validating this regulatorily-approved anatomic endpoint.

419 Our expectation of plume congruence with HFL trajectory was largely met and of
420 note was non-congruence near cRORA (Supplementary Table 6). This is likely due to
421 subsidence (sinking) of the OPL, HFL, and ONL, a committed step toward cRORA
422 onset.⁶⁷ Subsidence is visible where photoreceptors focally shorten and are scrolled by
423 Müller glia.^{7, 68} Our data on plume trajectories and CRALBP immunohistochemistry thus
424 add to prodigious activities of Müller glia in AMD. These include descent and curving of
425 the ELM (border of atrophy), reactive gliosis, adherent glial seal in areas of
426 photoreceptor depletion, and invasion of individual drusen.^{31, 44, 69, 70} CRALBP

427 immunohistochemistry confirmed HFL fiber geometry as well as retinoid capacity of
428 Müller glia, still supported by retinal circulation late in disease. Single and grouped RPE
429 organelles paralleling Müller glia ^{7, 71} are presumably carried intracellularly. In contrast
430 RPE cell bodies travel between HFL fibers ([Fig. 8L](#) and [Fig. 9](#)) following a trail of
431 organelle detritus. Active glial disassembly and removal of fragments is suspected.
432 Because almost 40% of plumes were not associated with atrophy at follow-up
433 (Supplementary Table 6), plumes should be considered indicators not predictors.
434 Factors underlying variable plume outcome in our study include inclusion of patients with
435 established disease, short observation period, and a “come and go” behavior consistent
436 with cells subject to constant pro-migratory stimuli being dismantled *en route*.

437 Given evidence that many RPE cells are transdifferentiating, HRF may indicate risk
438 by revealing an overall level and type of disease activity. Epithelial-mesenchyme-
439 transition (EMT) is one candidate activity. In this complex process, cells lose apical-
440 basal polarity, modulate cytoskeleton, and reduce cell-cell adhesion. ⁷² A defining
441 feature of an epithelium is localization within organs stabilized by a basal lamina and
442 integrin-mediated interactions with extracellular matrix. Epithelial cells that detach from
443 extracellular matrix normally undergo a programmed cell death called anoikis. ^{73, 74}
444 Tumor cells of epithelioid origin can escape anoikis by EMT. Thus, they assume
445 amoeboid morphology, become motile and invasive, and travel in the circulation to other
446 organs, with most dying *en route*. EMT of RPE has been suspected in AMD due to
447 findings of characteristic molecular markers (vimentin ⁷⁶ and the transcription factor
448 Snail1 ²¹) and the presence of HRF. ⁷⁵ Another contributor is the separation of the RPE-
449 BL from its native basal lamina by BLamD, ^{23, 77} an extracellular matrix that also contains
450 other components. RPE cells undergoing EMT might indeed resist cell death ²¹ but they

Cao, Leong et al, RPE transdifferentiation in AMD

451 may also be dysfunctional, due to gain- and loss-of-function suggested by our data. One
452 factor promoting EMT over anoikis is hypoxia,⁷⁴ of high AMD relevance due to age- and
453 disease-related loss of choroid and choriocapillaris⁷⁸⁻⁸¹ and the distancing of RPE from
454 choriocapillaris by BLamD and drusen.⁸² Thus we showed RPE cells not only contacting
455 the deep capillary plexus ([Fig. 9](#)^{17, 18}) but also aiming towards and clustering around
456 vessels as a seemingly coordinated group ([Fig. 9](#)) rather than as single cells. Parallels
457 with cancer are appropriate due to the unusual metabolic demands of photoreceptors
458 and their supporting system compared to other neurons. The retina, of all body tissues,
459 shares with tumors a dependence on aerobic glycolysis (the Warburg effect).⁸³⁻⁸⁵ A
460 consensus group of cancer researchers recently advocated monitoring cellular
461 properties as part of the main criteria for EMT, along with molecular markers.⁷² The high
462 OCT visibility of RPE makes it uniquely possible to view these cellular activities in AMD.

463 Strengths of the clinical study are high-quality images and long follow-up on known
464 progression risk factors. Limitations include the small number of patients and lack of
465 independently assessed HFL trajectory with directional OCT.⁸⁶ Strengths of the
466 laboratory study are short post-mortem specimens with attached retinas, comprehensive
467 photomicroscopy to visualize pigment, a color-contrasting readout for immunoreactivity,
468 and a cross-sectional format conducive to OCT comparison. Limitations addressable in
469 future studies include lack of clinical records with pre-mortem imaging, lack of correlative
470 data from flat mounts to show early RPE pathology, limited assessments of RPE
471 adjacent to AMD deposits, and lack of double-label experiments to determine cell-by-cell
472 overlap among the four markers. Nevertheless, this is most detailed characterization of
473 RPE pathology in AMD to date in either clinical or laboratory settings. HRF are a
474 consensus OCT feature in AMD,¹⁰ encouraging longitudinal studies in other clinical

Cao, Leong et al, RPE transdifferentiation in AMD

475 centers, ideally with comprehensive *en face* OCT and fundus autofluorescence imaging
476 to determine the proportion of HRF that are RPE-derived. Our data can propel new
477 biomarker and therapeutic strategies for a common and currently untreatable cause of
478 impaired vision.
479

480 **SUPPLEMENTARY MATERIALS**

481 **Supplementary Figures**

482 Supplementary Figure 1. Henle fibers in the human macula.

483 Supplementary Figure 2. Positive and negative controls for immunohistochemistry

484 Supplementary Figure 3. Retinal pigment epithelium plumes exhibit directionality

485 Supplementary Figure 4. Duration and evolution of plumes

486 Supplementary Figure 5. Variations in RPE plume trajectory in atrophy.

487 Supplementary Figure 6. Gain- and loss-of-function of RPE and RPE-derived cells

488 Supplementary Figure 7. Dispersing melanosomes follow regionally specific trajectories

489 of Müller glia

490 **Supplementary Tables**

491 Supplementary Table 1. Antibodies used

492 Supplementary Table 2. Morphologic phenotypes of RPE and its basal lamina in AMD

493 Supplementary Table 3. Demographics of clinic patients and study eyes

494 Supplementary Table 4. Plume disposition at final visit

495 Supplementary Table 5. Plume trajectory relative to HFL and macular quadrant

496 Supplementary Table 6. Plume association with atrophy

497 Supplementary Table 7. Characteristics of donor eyes

498

499

500 **Acknowledgments**

501 We thank Advancing Sight Network (formerly the Alabama Eye Bank) for timely retrieval
502 of donor eyes and David Fisher for graphics in Figure 1.

503 **Funding**

504 This work was supported by National Institutes of Health (Bethesda, MD, USA) grant
505 R01EY015520 (CAC); The Macula Foundation, Inc., New York, NY; an anonymous
506 donor to AMD research at UAB; unrestricted funds to the Department of Ophthalmology
507 from Research to Prevent Blindness, Inc.; and EyeSight Foundation of Alabama.
508 Acquisition of human tissues for immunohistochemistry was funded by NIH grant
509 R01EY015520 (CAC) and R01EY027948 (CAC, TA) and IZKF Würzburg (N-304, TA).

510 **Author contributions**

511 C.A.C. designed, supervised study and wrote the manuscript. D.C. designed and
512 performed immunohistochemistry experiments. B.L. designed and conducted clinical
513 studies and wrote the manuscript. J.M. conducted *ex vivo* imaging, tissue cryosections,
514 and microscopy. D.K. made Fig. S1. T.A. edited manuscript. L.A.Y. and K.B.F designed
515 and supervised clinical study. K.B.F. edited manuscript. C.A.C. and T.A. raised funding.

516 **Competing interests**


517 T.A. receives research funding from Novartis and is a stockholder of MacRegen Inc.
518 K.B.F. is a consultant to Genentech, Optovue, Zeiss, Heidelberg Engineering, Allergan,
519 and Novartis. C.A.C. receives research funds from Genentech/ Hoffman LaRoche and
520 Heidelberg Engineering and is a stockholder of MacRegen Inc.

521 **Data and materials availability**

522 All other data associated with this study are present in the paper or the Supplementary
523 Materials. Materials are available upon request from the corresponding author.

524

525 **Figures and Captions**



526

527 **Figure 1. Hypothesis for complete retinal pigment epithelium (RPE) and outer**
528 **retinal atrophy (cRORA) in AMD⁹ based on histology and OCT**

529 This schematic for non-neovascular AMD is adapted from Zanzottera et al.⁴⁴ Six
530 morphologic phenotypes of RPE from a system of 15²⁷ are shown. (1) Age-normal
531 “nonuniform” RPE overlies Bruch’s membrane (BrM), which has abundant lipoprotein
532 particles (yellow). Basal laminar deposit (BLamD, green) is thickened basement
533 membrane material between the RPE cell body and native RPE basal lamina. RPE
534 organelles are melanosomes (black), lipofuscin (yellow), and mitochondria (pink).⁶ (2)
535 Anteriorly migrated RPE (“sloughed” and “intraretinal”) manifest clinically as HRF.
536 “Shedding” cells release organelle clusters¹⁵ (arrow) basally into BLamD, thought to
537 represent apoptosis. (3) Due to cell death and migration, the RPE layer disintegrates.

Cao, Leong et al, RPE transdifferentiation in AMD

538 “Dissociated” RPE are fully pigmented, nucleated cells scattered in the atrophic zone.

539 BLamD persists after RPE death. **(4)** “Subducted” cells containing RPE organelles,


540 appearing to originate from Dissociated cells (arrow), are flattened against BrM. **(5)**

541 “Subducted” cells migrate outside the atrophic area.

542

543

544




545

546 **Figure 2. Morphology of retinal pigment epithelium plumes.**

547 Examples from two eyes of one patient. (A) “Curvilinear” consists of hyperreflective
548 structures of consistent width, often arising from a soft druse and aiming towards the
549 outer plexiform layer. (B) “Thread” has a uniform and thin width, compared to
550 Curvilinear. (C) “Comma” has a wide base adjacent to the RPE layer and an anterior
551 taper. (D) “Vitelliform” is thick and arises from an acquired vitelliform lesion.²⁴

552

Cao, Leong et al, RPE transdifferentiation in AMD



553


554 **Figure 3. Retinal pigment epithelium plumes evolve over time.**

555 (A to E) Tracked optical coherence tomography B-scans of 5 different eyes with AMD
556 are shown with individualized colored frames and scale bars. Numbers in the lower right
557 corners indicate time elapsed in months since the baseline visit at 0 months. (A1 to A4)
558 Hyperreflective foci (HRF) overlie a drusenoid pigment epithelial detachment that
559 collapsed at 12 months. HRF evolve into a comma plume before disappearing into
560 complete outer retinal atrophy (cORA⁹). (B1 to B6) A curvilinear plume evolves into a
561 vitelliform plume, which collapses, leaving atrophy and degenerative cysts. (C1 to C3) A
562 comma-type plume evolves into HRF upon drusen collapse. (D1 to D3) Of two thread
563 plumes at baseline, one (left) becomes curvilinear at 3 months and persists through
564 drusen collapse and *incomplete* RPE and outer retinal atrophy at 13 months. Thread
565 plume at the right has disappeared at 13 months. (E1 to E2) Two thread plumes evolve
566 into a comma plume as an RPE elevation appears. This eye also has an epiretinal
567 membrane.

Cao, Leong et al, RPE transdifferentiation in AMD

568

Cao, Leong et al, RPE transdifferentiation in AMD



569

570 **Figure 4. HRF in *ex vivo* OCT match intraretinal RPE on histology.**


571 Reflective features including hyperreflective foci (HRF) are visible in donor eyes (eye
572 numbers in Supplementary Table 7) by *ex vivo* optical coherence tomography (A1 to
573 F1). These were matched with RPE phenotypes in histology sections stained with
574 periodic acid Schiff hematoxylin (PASH) (A2 to F2), to show Bruch's membrane (BrM),
575 basal laminar deposit, and drusen. In all panels, scale bars are 200 μm; yellow
576 arrowheads indicate BrM, and green arrowheads indicate HRF in OCT and ectopic RPE
577 in histology. **(A1 and A2)** HRFs above soft drusen at fovea from early-intermediate AMD
578 eye (#5). **(B1 and B2)** HRFs at the fovea and nasal and temporal side, from atrophic
579 AMD eye (#17). **(C1 and C2)** RPE plume in atrophic AMD eye (#15). **(D1 and D2)**
580 Hyperreflective dots in OCT and dissociated RPE atop thick BLamD in the atrophic area.
581 **(E1 and E2)** Reflective dots under an island of surviving photoreceptors in the fovea

Cao, Leong et al, RPE transdifferentiation in AMD

582 center of an atrophic AMD eye (#12). (**F1** and **F2**) Multiple HRFs nasal to the fovea in an
583 early-intermediate AMD eye (#7), corresponding to intraretinal RPE cells.

584

Cao, Leong et al, RPE transdifferentiation in AMD



585


586 **Figure 5. RPE corresponding to HRF and other abnormal cells are CD68+.**

587 Twenty donor eyes (16 AMD, 4 controls; eye numbers in [Supplementary Table 7](#)) were
588 used for immunohistochemistry with mouse monoclonal anti-human CD68
589 (Supplementary Table 1) and red reaction product. Fourteen of 16 previously described
590 morphologic phenotypes of RPE²⁷ were identified (Supplementary Table 2). All scale
591 bars are 20 μm; yellow arrowheads indicate BrM, and green arrowheads indicate
592 abnormal RPE phenotypes. (A) CD68- “Uniform” RPE, unremarkable (#1). (B) CD68-
593 granule aggregates, released basally from “Shedding” RPE; atrophic AMD (#13). (C)
594 CD68+ “Sloughed” RPE; atrophic AMD (#12). (D) Both CD68+ and CD68- “Entombed”
595 RPE; nvAMD (#18). (E) A single CD68+ “Nonuniform” RPE from a less-affected area,
596 nvAMD (#20). (F) CD68+ “Intraretinal” RPE; early-intermediate AMD (#7). (G) Variable
597 CD68 immunoreactivity in “Melanotic” RPE, nvAMD (#18). CD68 immunoreactivity is
598 variable on heavily and light pigmented melanotic RPE. (H) CD68+ “Severe” RPE;
599 atrophic AMD (#13). (I) CD68+ “Subducted” RPE, atrophic AMD (#12). (J) CD68+
600 “Entubulated” RPE, atrophic AMD (#12). (K) CD68+ “Dissociated” RPE, atrophic AMD

Cao, Leong et al, RPE transdifferentiation in AMD

601 (#12). **(L)** CD68+ “Dissociated” RPE and “Sloughed” RPE, early-intermediate AMD (#7).
602 **(M)** Variable CD68 immunoreactivity in “Bilaminar” RPE, nvAMD (#20). **(N)** CD68+
603 “Dissociated” RPE; atrophic AMD (#12).
604

Cao, Leong et al, RPE transdifferentiation in AMD



605


606 **Figure 6. RPE corresponding to HRF and other abnormal cells are CD163+.**

607 Twenty donor eyes (16 AMD, 4 controls; eye number in Supplementary Table 7) were
608 used for immunohistochemistry with mouse monoclonal anti-human CD163
609 (Supplementary Table 1) and red reaction product. Fourteen of 16 previously described
610 morphologic phenotypes of RPE were identified (Supplementary Table 2). All scale bars
611 are 20 μ m; yellow arrowheads indicate BrM, and green arrowheads indicate abnormal
612 RPE phenotypes. (A) CD163- “Uniform” RPE, unremarkable (#1). (B) CD163-
613 “Shedding” RPE, nvAMD (#20). (C) CD163+ “Sloughed”, nvAMD (#20). (D) Both
614 CD163+ and CD163- are present in “Entombed” RPE, nvAMD (#20). (E) A single
615 CD163+migrating RPE above “Nonuniform” RPE layer, atrophic AMD (#17). (F) CD163+
616 “Intraretinal” RPE, atrophic AMD (#15). (G) Variable CD163 immunoreactivities in
617 “Melanotic” RPE, nvAMD (#20). (H) CD163+ “Severe” or “Very nonuniform” RPE,
618 nvAMD (#20). (I) CD163+ “Subducted” and “Sloughed” RPE, atrophic AMD (#16). (J)
619 CD163+ “Entubulated” and “Dissociated” RPE, nvAMD (#20). (K) There is no RPE in an
620 area of “Atrophy without BLamD”, atrophic AMD (#16). (L) CD163+ “Dissociated” and

Cao, Leong et al, RPE transdifferentiation in AMD

621 “Intraretinal” RPE, atrophic AMD (#16). **(M)** Variable CD163 immunoreactivity in
622 “Bilaminar” RPE, nAMD (#20). **(N)** CD163+ “Intraretinal” RPE at “Atrophy with BLamD”
623 area, atrophic AMD (#14).
624
625

Cao, Leong et al, RPE transdifferentiation in AMD



626

627 **Figure 7. RPE corresponding to HRF are RPE65-, as are other abnormal cells.**

628 Twenty donor eyes (16 AMD, 4 controls; eye numbers in [Supplementary Table 7](#)) were
629 used for immunohistochemistry with mouse monoclonal anti-human RPE65
630 (Supplementary Table 1) and red reaction product. Fourteen of 16 previously described
631 morphologic phenotypes of RPE²⁷ were identified (Supplementary Table 2). All scale
632 bars are 20 μm; yellow arrowheads indicate BrM; green and fuchsia arrowheads indicate
633 RPE65- and RPE65+ abnormal RPE phenotypes, respectively. (A) RPE65+ “Uniform”
634 RPE, unremarkable (#1). (B) RPE65- “Shedding” RPE, nvAMD (#20). (C) RPE65-
635 “Sloughed” RPE, atrophic AMD (#13). (D) Both RPE65+ and RPE65- “Entombed” RPE,
636 nvAMD (#18). (E) A few RPE65- “Nonuniform” RPE, early-intermediate AMD (#6). (F)
637 RPE65- “Intraretinal” RPE, early-intermediate AMD (#11). (G) Variable RPE65
638 immunoreactive “Melanotic” RPE, nvAMD (#18). (H) RPE65- “Severe” RPE, atrophic
639 AMD (#12). (I) RPE65- “Subducted” RPE, atrophic AMD (#12). (J) Both RPE65+ and
640 RPE65- “Entubulated” RPE, atrophic AMD (#12). (K) RPE65- RPE at “Atrophy without
641 BLamD” area, atrophic AMD (#12). (L) RPE65- “Dissociated” RPE, atrophic AMD (#16).

Cao, Leong et al, RPE transdifferentiation in AMD


642 **(M)** Both RPE65- and RPE65+ “Bilaminar” RPE, nvAMD (#20). **(N)** RPE65- RPE at

643 “Atrophy with BLamD” area, atrophic AMD (#13).

644

645

Cao, Leong et al, RPE transdifferentiation in AMD



646

647 **Figure 8. Abnormal RPE is CRALBP-, Müller glia are CRALBP+.**


648 Twenty donor eyes (16 AMD, 4 controls; eye numbers in [Supplementary Table 7](#)) were
649 used for immunohistochemistry with mouse monoclonal anti-human CRALBP
650 (Supplementary Table 1) and red reaction product. Fourteen of 16 previously described
651 morphologic phenotypes of RPE²⁷ were identified (Supplementary Table 2). All scale
652 bars are 20 μm. Yellow arrowheads indicate BrM. Green and fuchsia arrowheads
653 indicate CRALBP- and CRALBP+ abnormal RPE phenotypes, respectively. In panel L,
654 labeled Müller glia are seen at the external limiting membrane (ELM), pericellular
655 baskets in ONL (orange arrowhead), and parallel fibers in HFL. (A) CRALBP+ “Uniform”
656 RPE, unremarkable (#1). (B) CRALBP- “Shedding” RPE, early-intermediate AMD (#6).
657 (C) CRALBP- “Sloughed” RPE, atrophic AMD (#13). (D) Both CRALBP+ and CRALBP-
658 “Entombed” RPE nvAMD (#18). (E) CRALBP- “Nonuniform” RPE nvAMD (#18). (F)
659 CRALBP- “Intraretinal” RPE, early-intermediate AMD eye (#7). (G) Both CRALBP+ and
660 CRALBP- “Melanotic” RPE, nvAMD (#18). (H) CRALBP- “Severe” RPE, atrophic AMD
661 (#12). (I) CRALBP- “Subducted” RPE, atrophic AMD (#12). (J) Both CRALBP+ and

Cao, Leong et al, RPE transdifferentiation in AMD

662 CRALBP- “Entubulated” RPE, atrophic AMD (#12). **(K)** CRALBP- RPE at “Atrophy
663 without BLamD” area, atrophic AMD (#12). **(L)** CRALBP- “Dissociated” RPE, early-
664 intermediate AMD (#7). **(M)** Variable CRALBP immunoreactivity in “Bilaminar” RPE,
665 nvAMD (#20). **(N)** Variable CRALBP+ and CRALBP- RPE at “Atrophy with BLamD”
666 area, nvAMD (#7).

667

668



669

670 **Figure 9. RPE migrate toward vessels and follow Müller glial columns.**

671 One eye from each of two donors aged 86-90 years (#5 and #15, Supplementary Table

672 7) were subjected to *ex vivo* OCT images in A (Fig. 4, C1 and C2) and PASH staining

673 with cryosections in B, E and F. (A) *Ex vivo* OCT of donor eye (#5) shows HRF (yellow

674 arrowhead) over a large druse. (B) Corresponding PASH histologic section 290 μ m

675 superior to the fovea with a big druse (d), artifactually detached (x) from the RPE, and

676 thinner ONL. (C) Magnified RPE rosette in B (yellow arrowheads) crossing the HFL and

Cao, Leong et al, RPE transdifferentiation in AMD

677 approaching retinal capillaries (green arrowheads). **(D)** Nucleated RPE rosette from
678 panel C (adjacent section). RPE-characteristic spindle-shaped melanosomes and
679 melanolipofuscin impart a brown hue. The surrounded capillary is stained light pink
680 (green arrowhead) with endothelial cell nuclei. Processes containing RPE organelles
681 extend along the capillaries. **(E and F)** In another plume, RPE cells and detritus take a Z-
682 shaped course. Fully pigmented RPE cells cross the obliquely oriented fibers of the HFL,
683 with individual and grouped organelles in the lead (thin yellow arrows). The path turns
684 vertically to enter and cross the INL and IPL.
685

686 **References**

- 687 1. Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and
688 distance vision impairment 1990-2020: a systematic review and meta-analysis. *The*
689 *Lancet Global Health* 2017;5:e1221-e1234. PMID 29032195
- 690 2. Maguire MG, Martin DF, Ying GS, et al. Five-year outcomes with anti-vascular
691 endothelial growth factor treatment of neovascular age-related macular degeneration:
692 the Comparison of Age-Related Macular Degeneration Treatments Trials.
693 *Ophthalmology* 2016;123:1751-1761. PMID 27156698
- 694 3. Chen L, Messinger JD, Kar D, Duncan JL, Curcio CA. Biometrics, impact, and
695 significance of basal linear deposit and subretinal drusenoid deposit in age-related
696 macular degeneration. *Invest Ophthalmol Vis Sci* 2021;62:33. PMID 33512402
- 697 4. Keane PA, Patel PJ, Liakopoulos S, Heussen FM, Sadda SR, Tufail A. Evaluation
698 of age-related macular degeneration with optical coherence tomography. *Surv*
699 *Ophthalmol* 2012;57:389-414. PMID 22898648
- 700 5. Guymer RH, Rosenfeld PJ, Curcio CA, et al. Incomplete retinal pigment epithelial
701 and outer retinal atrophy (iRORA) in age-related macular degeneration: CAM Report 4.
702 *Ophthalmology* 2020;127:394-409. PMID 31708275
- 703 6. Pollreisz A, Neschi M, Sloan KR, et al. An atlas of human retinal pigment
704 epithelium organelles significant for clinical imaging. *Invest Ophthalmol Vis Sci*
705 2020;61:13. PMID 32648890
- 706 7. Li M, Huisinigh C, Messinger JD, et al. Histology of geographic atrophy secondary
707 to age-related macular degeneration: a multilayer approach. *Retina* 2018;38:1937-1953.
708 PMID 29746415
- 709 8. Holz FG, Sadda S, Staurenghi G, et al. Imaging protocols for clinical studies in
710 age-related macular degeneration – recommendations from Classification of Atrophy
711 (CAM) Consensus Meeting. *Ophthalmology* 2017;124:464-478. PMID 28109563
- 712 9. Sadda SR, Guymer R, Holz FG, et al. Consensus definition for atrophy associated
713 with age-related macular degeneration on optical coherence tomography: CAM Report
714 3. *Ophthalmology* 2018;125:537-548. PMID 29103793
- 715 10. Jaffe GJ, Chakravarthy U, Freund KB, et al. Imaging features associated with
716 progression to geographic atrophy in age-related macular degeneration: CAM Report 5.
717 *Ophthalmology Retina* 2020;12/20/20 online. PMID 33348085
- 718 11. Ouyang Y, Heussen FM, Hariri A, Keane PA, Sadda SR. Optical coherence
719 tomography-based observation of the natural history of drusenoid lesion in eyes with dry
720 age-related macular degeneration. *Ophthalmology* 2013;120:2656-2665. PMID
721 23830761
- 722 12. Christenbury JG, Folgar FA, O'Connell RV, Chiu SJ, Farsiu S, Toth CA.
723 Progression of intermediate age-related macular degeneration with proliferation and
724 inner retinal migration of hyperreflective foci. *Ophthalmology* 2013;120:1038-1045. PMID
725 23352193
- 726 13. Nassisi M, Lei J, Abdelfattah NS, et al. OCT risk factors for development of late
727 age-related macular degeneration in the fellow eyes of patients enrolled in the HARBOR
728 study. *Ophthalmology* 2019;126:1667-1674. PMID 31281056
- 729 14. Waldstein SM, Vogl W-D, Bogunovic H, Sadeghipour A, Riedl S, Schmidt-Erfurth
730 U. Characterization of drusen and hyperreflective foci as biomarkers for disease
731 progression in age-related macular degeneration using artificial intelligence in optical
732 coherence tomography. *JAMA Ophthalmology* 2020;138:740-747. PMID 32379287

- 733 15. Zanzottera EC, Messinger JD, Ach T, Smith RT, Freund KB, Curcio CA. The
734 Project MACULA retinal pigment epithelium grading system for histology and optical
735 coherence tomography in age-related macular degeneration. *Invest Ophthalmol Vis Sci*
736 2015;56:3253-3268. PMID 25813989
- 737 16. Zanzottera EC, Messinger JD, Ach T, Smith RT, Curcio CA. Subducted and
738 Melanotic cells in advanced age-related macular degeneration are derived from retinal
739 pigment epithelium. *Invest Ophthalmol Vis Sci* 2015;56:3269-3278. PMID 26024109
- 740 17. Balaratnasingam C, Messinger JD, Sloan KR, Yannuzzi LA, Freund KB, Curcio
741 CA. Histologic and optical coherence tomographic correlations in drusenoid pigment
742 epithelium detachment in age-related macular degeneration. *Ophthalmology*
743 2017;124:644-656. PMID 28153442
- 744 18. Li M, Dolz-Marco R, Messinger JD, et al. Clinicopathologic correlation of anti-
745 vascular endothelial growth factor-treated type 3 neovascularization in age-related
746 macular degeneration. *Ophthalmology* 2018;125:276-287. PMID 28964579
- 747 19. Jopling C, Boue S, Izpisua Belmonte JC. Dedifferentiation, transdifferentiation and
748 reprogramming: three routes to regeneration. *Nat Rev Mol Cell Biol* 2011;12:79-89.
749 PMID 21252997
- 750 20. Pang C, Messinger JD, Zanzottera EC, Freund KB, Curcio CA. The Onion Sign in
751 neovascular age-related macular degeneration represents cholesterol crystals.
752 *Ophthalmology* 2015;122:2316-2326. PMID 26298717
- 753 21. Ghosh S, Shang P, Terasaki H, et al. A role for betaA3/A1-crystallin in Type 2 EMT
754 of RPE cells occurring in dry age-related macular degeneration. *Invest Ophthalmol Vis*
755 *Sci* 2018;59:AMD104-AMD113. PMID 30098172
- 756 22. Staurengi G, Sadda S, Chakravarthy U, Spaide RF. Proposed lexicon for
757 anatomic landmarks in normal posterior segment spectral-domain optical coherence
758 tomography: The IN*OCT Consensus. *Ophthalmology* 2014;121:1572-1578. PMID
759 24755005
- 760 23. Sura AA, Chen L, Messinger JD, et al. Measuring the contributions of basal laminar
761 deposit and Bruch's membrane in age-related macular degeneration. *Invest Ophthalmol*
762 *Vis Sci* 2020;61:19. PMID 33186466
- 763 24. Freund KB, Laud K, Lima LH, Spaide RF, Zweifel S, Yannuzzi LA. Acquired
764 vitelliform lesions: correlation of clinical findings and multiple imaging analyses. *Retina*
765 2011;31:13-25. PMID 21102371
- 766 25. Tan ACS, Freund KB, Balaratnasingam C, Simhae D, Yannuzzi LA. Imaging of
767 pigment epithelial detachments with optical coherence tomography angiography. *Retina*
768 2018;38:1759-1769. PMID 29293207
- 769 26. Jakobiec FA, Barrantes PC, Yonekawa Y, Lad EM, Proia AD. Subretinal
770 mononuclear cells in Coats' disease studied with RPE65 and CD163: evidence for
771 histiocytoid pigment epithelial cells. *American Journal of Ophthalmology* 2020;222:388-
772 396. PMID 32950512
- 773 27. Curcio CA, Zanzottera EC, Ach T, Balaratnasingam C, Freund KB. Activated retinal
774 pigment epithelium, an optical coherence tomography biomarker for progression in age-
775 related macular degeneration. *Invest Ophthalmol Vis Sci* 2017;58: BIO211-BIO226.
776 PMID 28785769
- 777 28. Sparrow JR, Marsiglia M, Allikmets R, et al. Flecks in recessive Stargardt disease:
778 short-wavelength autofluorescence, near-infrared autofluorescence, and optical
779 coherence tomography. *Invest Ophthalmol Vis Sci* 2015;56:5029-5039. PMID 26230768

- 780 29. Barros MH, Hauck F, Dreyer JH, Kempkes B, Niedobitek G. Macrophage
781 polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages.
782 *PLoS One* 2013;8:e80908. PMID 24260507
- 783 30. Chistiakov DA, Killingsworth MC, Myasoedova VA, Orekhov AN, Bobryshev YV.
784 CD68/macrosialin: not just a histochemical marker. *Lab Invest* 2017;97:4-13. PMID
785 27869795
- 786 31. Schaal KB, Freund KB, Litts KM, Zhang Y, Messinger JD, Curcio CA. Outer retinal
787 tubulation in advanced age-related macular degeneration: optical coherence
788 tomographic findings correspond to histology. *Retina* 2015;35:1339-1350. PMID
789 25635579
- 790 32. Etzerodt A, Moestrup SK. CD163 and inflammation: biological, diagnostic, and
791 therapeutic aspects. *Antioxid Redox Signal* 2013;18:2352-2363. PMID 22900885
- 792 33. Karlstetter M, Scholz R, Rutar M, Wong WT, Provis JM, Langmann T. Retinal
793 microglia: just bystander or target for therapy? *Prog Retin Eye Res* 2015;45:30-57. PMID
794 25476242
- 795 34. Lad EM, Cousins SW, Proia AD. Identity of pigmented subretinal cells in age-
796 related macular degeneration. *Graefes Arch Clin Exp Ophthalmol* 2016;254:1239-1241.
797 PMID 26728757
- 798 35. Margeta MA, Lad EM, Proia AD. CD163+ macrophages infiltrate axon bundles of
799 postmortem optic nerves with glaucoma. *Graefes Arch Clin Exp Ophthalmol*
800 2018;256:2449-2456. PMID 30073622
- 801 36. Lamb TD, Pugh EN, Jr. Phototransduction, dark adaptation, and rhodopsin
802 regeneration: the Proctor Lecture. *Invest Ophthalmol Vis Sci* 2006;47:5137-5152. PMID
803 17122096
- 804 37. Saari JC. Vitamin A and Vision. *Subcell Biochem* 2016;81:231-259. PMID
805 27830507
- 806 38. von Lintig J, Moon J, Babino D. Molecular components affecting ocular carotenoid
807 and retinoid homeostasis. *Prog Retin Eye Res* 2021;80:100864. PMID 32339666
- 808 39. Xue Y, Shen SQ, Jui J, et al. CRALBP supports the mammalian retinal visual cycle
809 and cone vision. *J Clin Invest* 2015;125:727-738. PMID 25607845
- 810 40. Liu T, Jenwitheesuk E, Teller DC, Samudrala R. Structural insights into the cellular
811 retinaldehyde-binding protein (CRALBP). *Proteins* 2005;61:412-422. PMID 16121400
- 812 41. Ach T, Tolstik E, Messinger JD, Zarubina AV, Heintzmann R, Curcio CA.
813 Lipofuscin re-distribution and loss accompanied by cytoskeletal stress in retinal pigment
814 epithelium of eyes with age-related macular degeneration. *Invest Ophthalmol Vis Sci*
815 2015;56:3242-3252. PMID 25758814
- 816 42. Omri S, Omri B, Savoldelli M, et al. The outer limiting membrane (OLM) revisited:
817 clinical implications. *Clin Ophthalmol* 2010;4:183-195. PMID 20463783
- 818 43. Polyak SL. *The Retina*. Chicago: University of Chicago; 1941.
- 819 44. Zanzottera EC, Ach T, Huisinigh C, Messinger JD, Spaide RF, Curcio CA.
820 Visualizing retinal pigment epithelium phenotypes in the transition to geographic atrophy
821 in age-related macular degeneration. *Retina* 2016;36 Suppl 1:S12-S25. PMID 27658287
- 822 45. Matet A, Savastano MC, Rispoli M, et al. En face optical coherence tomography of
823 foveal microstructure in full-thickness macular hole: a model to study perifoveal Muller
824 cells. *Am J Ophthalmol* 2015;159:1142-1151 e1143. PMID 25728860
- 825 46. Lei J, Balasubramanian S, Abdelfattah NS, Nittala M, Sadda SR. Proposal of a
826 simple optical coherence tomography-based scoring system for progression of age

- 827 related macular degeneration. *Graefes Arch Clin Exp Ophthalmol* 2017;255:1551-1558.
828 PMID 28534244
- 829 47. Nicolai U, Eckardt C. The occurrence of macrophages in the retina and periretinal
830 tissues in ocular diseases. *Ger J Ophthalmol* 1993;2:195-201. PMID 8220098
- 831 48. Sheridan C, Hiscott P, Grierson I. Retinal pigment epithelium differentiation and
832 dedifferentiation. In: Kirchhof B, Wong D (eds), *Vitreo-retinal Surgery Essentials in*
833 *Ophthalmology* Berlin, Heidelberg: Springer; 2005.
- 834 49. Bonilha VL, Bell BA, Hu J, et al. Geographic atrophy: confocal scanning laser
835 ophthalmoscopy, histology, and inflammation in the region of expanding lesions. *Invest*
836 *Ophthalmol Vis Sci* 2020;61:15. PMID 32658960
- 837 50. Matsubara JA, Tian Y, Cui JZ, et al. Retinal distribution and extracellular activity of
838 granzyme B: a serine protease that degrades retinal pigment epithelial tight junctions
839 and extracellular matrix proteins. *Front Immunol* 2020;11:574. PMID 32318066
- 840 51. Chen KC, Jung JJ, Curcio CA, et al. Intraretinal hyperreflective foci in acquired
841 vitelliform lesions of the macula: clinical and histologic study. *Am J Ophthalmol*
842 2016;164:89-98. PMID 26868959
- 843 52. Cherepanoff S, McMenamin PG, Gillies MC, Kettle E, Sarks SH. Bruch's
844 membrane and choroidal macrophages in early and advanced age-related macular
845 degeneration. *Br J Ophthalmol* 2010;94:918-925. PMID 19965817
- 846 53. McLeod DS, Bhutto I, Edwards MM, Silver RE, Seddon JM, Luty GA. Distribution
847 and quantification of choroidal macrophages in human eyes with age-related macular
848 degeneration. *Invest Ophthalmol Vis Sci* 2016;57:5843-5855. PMID 27802514
- 849 54. Elner SG, Elner VM, Nielsen JC, Torczynski E, Yu R, Franklin WA. CD68 antigen
850 expression by human retinal pigment epithelial cells. *Exp Eye Res* 1992;55:21-28. PMID
851 1397126
- 852 55. Tatar O, Yoeruek E, Szurman P, et al. Effect of bevacizumab on inflammation and
853 proliferation in human choroidal neovascularization. *Arch Ophthalmol* 2008;126:782-790.
854 PMID 18541840
- 855 56. Sheridan CM, Pate S, Hiscott P, Wong D, Pattwell DM, Kent D. Expression of
856 hypoxia-inducible factor-1 α and -2 α in human choroidal neovascular
857 membranes. *Graefes Arch Clin Exp Ophthalmol* 2009;247:1361-1367. PMID 19590888
- 858 57. Ghazi-Nouri SM, Assi A, Limb GA, et al. Laser photocoagulation alters the pattern
859 of staining for neurotrophin-4, GFAP, and CD68 in human retina. *Br J Ophthalmol*
860 2003;87:488-492. PMID 12642316
- 861 58. Simsek M, Ozates S, Gulpamuk B, Buyukeren B, Teke MY. Dedifferentiation of
862 retinal pigment epithelium in a patient with chronic retinal detachment. *Ophthalmic Surg*
863 *Lasers Imaging Retina* 2018;49:716-720. PMID 30222808
- 864 59. Josifovska N, Lumi X, Szatmari-Toth M, et al. Clinical and molecular markers in
865 retinal detachment-From hyperreflective points to stem cells and inflammation. *PLoS*
866 *One* 2019;14:e0217548. PMID 31185026
- 867 60. Sarks JP, Sarks SH, Killingsworth MC. Evolution of geographic atrophy of the
868 retinal pigment epithelium. *Eye* 1988;2:552-577. PMID 2476333
- 869 61. Gocho K, Sarda V, Falah S, et al. Adaptive optics imaging of geographic atrophy.
870 *Invest Ophthalmol Vis Sci* 2013;54:3673-3680. PMID 23620431
- 871 62. Penfold PL, Killingsworth MC, Sarks SH. Senile macular degeneration: the
872 involvement of immunocompetent cells. *Graefes Arch Clin Exp Ophthalmol* 1985;223:69-
873 76. PMID 2408968

- 874 63. Sennlaub F, Auvynet C, Calippe B, et al. CCR2(+) monocytes infiltrate atrophic
875 lesions in age-related macular disease and mediate photoreceptor degeneration in
876 experimental subretinal inflammation in Cx3cr1 deficient mice. *EMBO Mol Med*
877 2013;5:1775-1793. PMID 24142887
- 878 64. Schlereth SL, Kremers S, SchrodL F, Cursiefen C, Heindl LM. Characterization of
879 antigen-presenting macrophages and dendritic cells in the healthy human sclera. *Invest*
880 *Ophthalmol Vis Sci* 2016;57:4878-4885. PMID 27654414
- 881 65. Shirazi MF, Brunner E, Laslandes M, Pollreisz A, Hitzemberger CK, Pircher M.
882 Visualizing human photoreceptor and retinal pigment epithelium cell mosaics in a single
883 volume scan over an extended field of view with adaptive optics optical coherence
884 tomography. *Biomed Opt Express* 2020;11:4520-4535. PMID 32923061
- 885 66. Lee B, Chen S, Moulton EM, et al. High-speed, ultrahigh-resolution spectral-domain
886 OCT with extended imaging range using reference arm length matching. *Translational*
887 *Vision Science & Technology* 2020;9:12-12. PMID 32832219
- 888 67. Wu Z, Luu CD, Hodgson LAB, et al. Prospective longitudinal evaluation of nascent
889 geographic atrophy in age-related macular degeneration. *Ophthalmol Retina* 2019.
890 PMID 32088159
- 891 68. Dolz-Marco R, Litts KM, Tan ACS, Freund KB, Curcio CA. The evolution of outer
892 retinal tubulation, a neurodegeneration and gliosis prominent in macular diseases.
893 *Ophthalmology* 2017;124:1353-1367. PMID 28456420
- 894 69. Edwards MM, McLeod DS, Bhutto IA, Grebe R, Duffy M, Luty GA. Subretinal glial
895 membranes in eyes with geographic atrophy. *Invest Ophthalmol Vis Sci* 2017;58:1352-
896 1367. PMID 28249091
- 897 70. Chen L, Messinger JD, Ferrara D, Freund KB, Curcio CA. Stages of drusen-
898 associated atrophy in age-related macular degeneration visible via histologically
899 validated fundus autofluorescence. *Ophthalmology Retina* 2020;11/30/20 online. PMID
900 33217617
- 901 71. Tan AC, Pilgrim M, Fearn S, et al. Calcified nodules in retinal drusen are
902 associated with disease progression with age-related macular degeneration. *Sci Transl*
903 *Med* 2018;10:466-477. PMID 30404862
- 904 72. Yang J, Antin P, Berx G, et al. Guidelines and definitions for research on epithelial-
905 mesenchymal transition. *Nat Rev Mol Cell Biol* 2020;21:341-352. PMID 32300252
- 906 73. Gilmore AP. Anoikis. *Cell Death Differ* 2005;12 Suppl 2:1473-1477. PMID
907 16247493
- 908 74. Paoli P, Giannoni E, Chiarugi P. Anoikis molecular pathways and its role in cancer
909 progression. *Biochim Biophys Acta* 2013;1833:3481-3498. PMID 23830918
- 910 75. Zhou M, Geathers JS, Grillo SL, et al. Role of epithelial-mesenchymal transition in
911 retinal pigment epithelium dysfunction. *Front Cell Dev Biol* 2020;8:501. PMID 32671066
- 912 76. Guidry C, Medeiros NE, Curcio CA. Phenotypic variation of retinal pigment
913 epithelium in age-related macular degeneration. *Invest Ophthalmol Vis Sci* 2002;43:267-
914 273. PMID 11773041
- 915 77. Curcio CA, Millican CL. Basal linear deposit and large drusen are specific for early
916 age-related maculopathy. *Archives of Ophthalmology* 1999;117:329-339. PMID
917 10088810
- 918 78. Ramrattan RS, van der Schaft TL, Mooy CM, de Bruijn WC, Mulder PGH, de Jong
919 PTVM. Morphometric analysis of Bruch's membrane, the choriocapillaris, and the
920 choroid in aging. *Invest Ophthalmol Vis Sci* 1994;35:2857-2864. PMID 8188481

Cao, Leong et al, RPE transdifferentiation in AMD

- 921 79. Mullins RF, Johnson MN, Faidley EA, Skeie JM, Huang J. Choriocapillaris vascular
922 dropout related to density of drusen in human eyes with early age-related macular
923 degeneration. *Investigative Ophthalmology & Visual Science* 2011;52:1606-1612. PMID
924 21398287
- 925 80. Seddon JM, McLeod DS, Bhutto IA, et al. Histopathological insights into choroidal
926 vascular loss in clinically documented cases of age-related macular degeneration. *JAMA*
927 *Ophthalmol* 2016;134:1272-1280. PMID 27657855
- 928 81. Luty GA, McLeod DS, Bhutto IA, Edwards MM, Seddon JM. Choriocapillaris
929 dropout in early age-related macular degeneration. *Exp Eye Res* 2020;107939. PMID
930 31987759
- 931 82. Balaratnasingam C, Yannuzzi LA, Curcio CA, et al. Associations between retinal
932 pigment epithelium and drusen volume changes during the lifecycle of large drusenoid
933 pigment epithelial detachments. *Invest Ophthalmol Vis Sci* 2016;57:5479-5489. PMID
934 27760262
- 935 83. Pan WW, Wubben TJ, Besirli CG. Photoreceptor metabolic reprogramming: current
936 understanding and therapeutic implications. *Commun Biol* 2021;4:245. PMID 33627778
- 937 84. Hurley JB, Lindsay KJ, Du J. Glucose, lactate, and shuttling of metabolites in
938 vertebrate retinas. *J Neurosci Res* 2015;93:1079-1092. PMID 25801286
- 939 85. Chinchore Y, Begaj T, Wu D, Drokhlyansky E, Cepko CL. Glycolytic reliance
940 promotes anabolism in photoreceptors. *Elife* 2017;6. PMID 28598329
- 941 86. Lujan B, Roorda A, Knighton RW, Carroll J. Revealing Henle's fiber layer using
942 spectral domain optical coherence tomography. *Invest Ophthalmol Vis Sci*
943 2011;52:1486–1492. PMID 21071737
944